TrialPediatric blood & cancer2020

Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.

Nirali N Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.